Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: Longitudinal data from the DETECT cohort

Annals of the Rheumatic Diseases

Volumn 77, Issue 1, 2018, Pages 128-132

  Mihai, Carina ^a,b   Antic, Milos ^b   Dobrota, Rucsandra ^a,b   Bonderman, Diana ^c   Chadha Boreham, Harbajan ^d   Coghlan, John Gerry ^e   Denton, Christopher P ^e   Doelberg, Martin ^d   Grünig, Ekkehard ^f   Khanna, Dinesh ^g   McLaughlin, Vallerie V ^g   Müller Ladner, Ulf ^h   Pope, Janet E ⁱ   Rosenberg, Daniel M ^d   Seibold, James R ^j,k   Vonk, Madelon C ^l   Distler, Oliver ^b  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ACTELION PHARMACEUTICALS LTD   (Switzerland)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h JUSTUS LIEBIG UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j Scleroderma Research Consultants   (United States)

^k MEDICAL COLLEGE OF GEORGIA   (United States)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE;

ADULT; AGED; ARTICLE; BORG DYSPNEA INDEX; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; DYSPNEA; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY TRACT DISEASE ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SYSTEMIC SCLEROSIS; COMPLICATION; CROSS-SECTIONAL STUDY; LUNG; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TOTAL LUNG CAPACITY;

ADULT; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; LOGISTIC MODELS; LONGITUDINAL STUDIES; LUNG; MALE; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TOTAL LUNG CAPACITY;

EID: 85038238925     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211480     Document Type: Article

References (14)

1. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24.
2. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-Term survival. Arthritis Rheum 2011;63:3522-30.
3. Galié N, Humbert M, Vachiery JL, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2015;37:67-119.
4. Coghlan JG, Denton CP, Grünig E, et al. DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: The DETECT study. Ann Rheum Dis 2014;73:1340-9.
5. Galiè N, Barberà JA, Frost AE, et al. Initial use of Ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;373:834-44.
6. Lefèvre G, Dauchet L, Hachulla E, et al. Survival and prognostic factors in systemic sclerosis-Associated pulmonary hypertension: A systematic review and meta-Analysis. Arthritis Rheum 2013;65:2412-23.
7. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-Associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-7.
8. Chung L, Farber HW, Benza R, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 2014;146:1494-504.
9. Chung L, Domsic RT, Lingala B, et al. Survival and predictors of mortality in systemic sclerosis-Associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res 2014;66:489-95.
10. Launay D, Sitbon O, Cordier JF, et al. Survival and prognostic factors in patients with incident and newly diagnosed SSc-Associated pulmonary arterial hypertension from the French Registry. Ann Rheum Dis 2013;72:1940-6.
11. Bryan C, Knight C, Black CM, et al. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999;42:2660-5.
12. Fransen J, Popa-Diaconu D, Hesselstrand R, et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011;70:1788-92.
13. Elhai M, Meune C, Avouac J, et al. A deep insight into causes and predictors of death in systemic sclerosis. Arthritis Rheumatol 2016;68.
14. Simonneau G, RobbinsIM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-S54.